This is a phase III trial of Zoledronate, a third generation bisphosphonate which is a more potent inhibitor of osteoclasts than earlier bisphosphonates, in two dose levels verskus pamidronate (Aredia). The latter drug has been shown (in combination with anti-neoplastic agents) to decrease significantly the proportion of patients with skeletal complications due to lytic bone disease associated with multiple myeloma and breast cancer.
Showing the most recent 10 out of 600 publications